Literature DB >> 22419574

Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites.

Ioanna Lazana1, Anastasia Zoudiari, Dimitra Kokkinou, Maria Themeli, Maria Liga, Helen Papadaki, Dionysios Papachristou, Alexandros Spyridonidis.   

Abstract

BACKGROUND: The human leukocyte antigen-G (HLA-G) has been considered to be an important tolerogeneic molecule playing an essential role in maternal-fetal tolerance, which constitutes the perfect example of successful physiological immunotolerance of semi-allografts. In this context, we investigated the putative role of this molecule in the allogeneic hematopoietic cell transplantation setting. DESIGN AND METHODS: The percentage of HLA-G(+) cells in peripheral blood of healthy donors and allo-transplanted patients was evaluated by flow cytometry. Their immunoregulatory and tolerogeneic properties were investigated in in vitro immunostimulatory and immunosuppression assays. Immunohistochemical analysis for HLA-G expression was performed in skin biopsies from allo-transplanted patients and correlated with the occurrence of graft-versus-host disease.
RESULTS: We identified a CD14(+)HLA-G(pos) population with an HLA-DR(low) phenotype and decreased in vitro immunostimulatory capacity circulating in peripheral blood of healthy individuals. Naturally occurring CD14(+)HLA-G(pos) cells suppressed T-cell responses and exerted an immunotolerogenic action on T cells by rendering them hyporesponsive and immunosuppressive in vitro. After allogeneic hematopoietic cell transplantation, HLA-G(pos) cells increase in blood. Interestingly, besides an increase in CD14(+)HLA-G(pos) cells, there was also a pronounced expansion of CD3(+)HLA-G(pos) cells. Of note, CD3(+)HLA-G(pos) and CD14(+)HLA-G(pos) cells from transplanted patients were suppressive in in vitro lymphoproliferation assays. Furthermore, we found an upregulation of HLA-G expression in skin specimens from transplanted patients that correlated with graft-versus-host disease. Inflammatory cells infiltrating the dermis of transplanted patients were also HLA-G(pos).
CONCLUSIONS: We report the presence of naturally occurring HLA-G(pos) monocytic cells with in vitro suppressive properties. HLA-G expressing regulatory blood cells were found in increased numbers after allogeneic transplantation. Epithelial cells in skin affected by graft-versus-host disease revealed elevated HLA-G expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419574      PMCID: PMC3436234          DOI: 10.3324/haematol.2011.055871

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  43 in total

1.  IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes.

Authors:  P Moreau; F Adrian-Cabestre; C Menier; V Guiard; L Gourand; J Dausset; E D Carosella; P Paul
Journal:  Int Immunol       Date:  1999-05       Impact factor: 4.823

2.  Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells.

Authors:  Solène Le Rond; Christine Azéma; Irène Krawice-Radanne; Antoine Durrbach; Catherine Guettier; Edgardo D Carosella; Nathalie Rouas-Freiss
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

3.  Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma.

Authors:  Y Yang; W Chu; D E Geraghty; J S Hunt
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

4.  Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.

Authors:  Meike Mitsdoerffer; Bettina Schreiner; Bernd C Kieseier; Oliver Neuhaus; Johannes Dichgans; Hans-Peter Hartung; Michael Weller; Heinz Wiendl
Journal:  J Neuroimmunol       Date:  2004-12-28       Impact factor: 3.478

5.  Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors.

Authors:  K G Lerner; G F Kao; R Storb; C D Buckner; R A Clift; E D Thomas
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

6.  HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?

Authors:  Nathalie Rouas-Freiss; Philippe Moreau; Soldano Ferrone; Edgardo D Carosella
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

7.  A strong association between down-regulation of HLA-DR expression and the late mortality in patients with severe acute pancreatitis.

Authors:  Yu-Pin Ho; I-Shyan Sheen; Cheng-Tang Chiu; Cheng-Shyong Wu; Chun-Yen Lin
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

8.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.

Authors:  Guillaume Monneret; Alain Lepape; Nicolas Voirin; Julien Bohé; Fabienne Venet; Anne-Lise Debard; Hélène Thizy; Jacques Bienvenu; François Gueyffier; Philippe Vanhems
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440

9.  HLA-G class I gene expression in normal and malignant hematopoietic cells.

Authors:  L Amiot; M Onno; B Drénou; C Monvoisin; R Fauchet
Journal:  Hum Immunol       Date:  1998-08       Impact factor: 2.850

Review 10.  Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.

Authors:  Robert Zeiser; Reinhard Marks; Hartmut Bertz; Jürgen Finke
Journal:  Ann Hematol       Date:  2004-06-15       Impact factor: 3.673

View more
  3 in total

Review 1.  Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  F1000Res       Date:  2017-05-03

Review 2.  Tregs and kidney: From diabetic nephropathy to renal transplantation.

Authors:  Periklis Dousdampanis; Kostantina Trigka; Athanasia Mouzaki
Journal:  World J Transplant       Date:  2016-09-24

Review 3.  HLA-G Expressing Immune Cells in Immune Mediated Diseases.

Authors:  P Contini; Giuseppe Murdaca; Francesco Puppo; Simone Negrini
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.